Martha R. Feller, Ph.D., has been promoted to senior vice president, global clinical development,
Kendle. Also,
Ubavka M. Denoble, M.D. and
Judith H. Swilley, Ph.D., have been appointed vice president and senior director, global clinical development, North America, respectively. These appointments are part of an effort to strengthen the company's global clinical development leadership team to drive continued growth in its Phase II-III business worldwide.
Dr. Feller will provide executive leadership for the company's Phase II-III operations in North America, Europe, Asia/Pacific, Latin America and Africa. Dr. Denoble and Dr. Swilley will provide strategic oversight and direction for the company's Phase II-III clinical development activities in North America, where each will be responsible for specialized therapeutic and dedicated customer account teams in this region. Dr. Denoble and Dr. Swilley will report to Dr. Feller.
Dr. Feller has nearly 30 years of CRO and pharmaceutical industry experience. She most recently served as senior vice president, global clinical development, North America, a position she has held since joining the company in 2004 from Procter & Gamble Pharmaceuticals. She has expertise in all phases of drug development for both prescription and OTC products across multiple therapeutic areas.
Dr. Denoble has served as vice president, global safety and pharmacovigilance, since joining the company in 2006 as part of the Charles River Clinical Services acquisition. In this role, she has provided strategic leadership for the global safety function. She has more than 20 years of CRO and clinical experience, including executive roles in medical affairs, safety/pharmacovigilance and clinical development. She has expertise in ophthalmology and cardiovascular therapeutic areas.
Dr. Swilley has served as a senior director, global clinical development, North America since joining the company in 2006 as part of the Charles River Clinical Services acquisition. In this role, she provides leadership for Phase II-III projects worldwide. Dr. Swilley has more than 20 years of clinical and training experience in the CRO and pharmaceutical industries, including senior positions in clinical monitoring and staff training and development. She has expertise in oncology, infectious disease and dermatology therapeutic areas.
Magazine
